Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

194.70USD
18 Jan 2019
Change (% chg)

$4.18 (+2.19%)
Prev Close
$190.52
Open
$192.63
Day's High
$194.78
Day's Low
$189.41
Volume
867,387
Avg. Vol
569,364
52-wk High
$194.85
52-wk Low
$144.15

Latest Key Developments (Source: Significant Developments)

Vertex Pharmaceuticals (Europe) Reports Open Market Buy Of 90,742 Shares Of CRISPR Therapeutics At Prices Ranging From $22.58/Share To $24.97/Share
Thursday, 27 Dec 2018 

Dec 26 (Reuters) - CRISPR Therapeutics AG ::VERTEX PHARMACEUTICALS (EUROPE) REPORTS OPEN MARKET BUY OF 90,742 SHARES OF CRISPR THERAPEUTICS AT PRICES RANGING FROM $22.58/SHARE TO $24.97/SHARE.  Full Article

Vertex Says To Submit Orkambi, Symkevi Medicines To Scotland For Appraisal
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX ANNOUNCES IT WILL SUBMIT CYSTIC FIBROSIS MEDICINES ORKAMBI (LUMACAFTOR/IVACAFTOR) AS WELL AS SYMKEVI (TEZACAFTOR/IVACAFTOR) TO BE USED IN COMBINATION WITH IVACAFTOR, TO THE SCOTTISH MEDICINES CONSORTIUM FOR APPRAISAL.VERTEX AND SCOTTISH GOVERNMENT HAVE AGREED A CONFIDENTIAL DISCOUNT WHICH WOULD BE APPLIED TO APPROVED PACS TIER 2 APPLICATIONS.IF DRUG IS ACCEPTED BY SMC FOR USE ON NHS IN SCOTLAND, ELIGIBLE PATIENTS WITH CYSTIC FIBROSIS SCOTLAND COULD HAVE ACCESS TO MEDICINES IN 2019.  Full Article

Vertex Announces Positive Phase 2 Data In Third Proof-Of-Concept Study With The NaV1.8 Inhibitor VX-150
Tuesday, 18 Dec 2018 

Dec 18 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX ANNOUNCES POSITIVE PHASE 2 DATA IN THIRD PROOF-OF-CONCEPT STUDY WITH THE NAV1.8 INHIBITOR VX-150.VERTEX PHARMACEUTICALS INC - VERTEX HAS INITIATED A PHASE 2B DOSE-RANGING STUDY TO EVALUATE VX-150 FOR ACUTE PAIN.VERTEX PHARMACEUTICALS INC - TREATMENT WITH NAV1.8 INHIBITOR VX-150 SHOWED SIGNIFICANT RELIEF OF PAIN IN PATIENTS.VERTEX PHARMACEUTICALS INC - VX-150 WAS GENERALLY WELL TOLERATED IN THIS STUDY.VERTEX PHARMACEUTICALS INC - EXPECTS TO ADVANCE ADDITIONAL NAV1.8 INHIBITORS INTO CLINICAL DEVELOPMENT BEGINNING IN 2019.VERTEX PHARMACEUTICALS INC - STUDY MET ITS PRIMARY ENDPOINT.VERTEX PHARMACEUTICALS INC - TREATMENT WITH VX-150 DEMONSTRATED STATISTICALLY SIGNIFICANT & CLINICALLY MEANINGFUL PAIN REDUCTION.VERTEX PHARMACEUTICALS INC - MAJORITY OF ADVERSE EVENTS WERE MILD OR MODERATE IN STUDY.VERTEX PHARMACEUTICALS - IN STUDY, ADVERSE EVENTS OCCURRED IN 63 PERCENT OF PATIENTS WHO RECEIVED VX-150 AND 56 PERCENT OF PATIENTS WHO RECEIVED PLACEBO.  Full Article

Vertex Pharmaceuticals - Thomas Graney Notified on Dec 13, He Is Resigning As CFO Effective Immediately
Monday, 17 Dec 2018 

Dec 17 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX PHARMACEUTICALS - ON DECEMBER 13, THOMAS GRANEY NOTIFIED HE IS RESIGNING AS CFO EFFECTIVE IMMEDIATELY.VERTEX PHARMACEUTICALS SAYS IAN F. SMITH ASSUMED ADDITIONAL ROLE OF INTERIM CFO ON DECEMBER 13 - SEC FILING.VERTEX PHARMACEUTICALS - GRANEY WILL CONTINUE AS EMPLOYEE AND ASSIST IN TRANSITION THROUGH FEB 2019.  Full Article

Health Canada Grants Market Authorization For ORKAMBI (Lumacaftor/Ivacaftor) For Children With Cystic Fibrosis Aged 2 To 5 Years Old With Most Common Form Of The Disease
Thursday, 13 Dec 2018 

Dec 13 (Reuters) - Vertex Pharmaceuticals Inc ::HEALTH CANADA GRANTS MARKET AUTHORIZATION FOR ORKAMBI® (LUMACAFTOR/IVACAFTOR) FOR CHILDREN WITH CYSTIC FIBROSIS AGED 2 TO 5 YEARS OLD WITH MOST COMMON FORM OF THE DISEASE.VERTEX PHARMACEUTICALS INC - EXPECTS A DECISION ON ORKAMBI FROM EUROPEAN COMMISSION IN COMING MONTHS.  Full Article

Vertex Announces European Commission Approval For Kalydeco (Ivacaftor)
Thursday, 29 Nov 2018 

Nov 29 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX ANNOUNCES EUROPEAN COMMISSION APPROVAL FOR KALYDECO® (IVACAFTOR) TO TREAT PATIENTS WITH CYSTIC FIBROSIS AGED 12 TO <24 MONTHS WITH CERTAIN MUTATIONS IN THE CFTR GENE.  Full Article

Vertex Reports Third-Quarter 2018 Financial Results
Thursday, 25 Oct 2018 

Oct 24 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX REPORTS THIRD-QUARTER 2018 FINANCIAL RESULTS.REITERATES FULL-YEAR 2018 TOTAL CF PRODUCT REVENUE GUIDANCE OF $2.9 TO $3.0 BILLION.REITERATES FULL-YEAR 2018 COMBINED NON-GAAP RESEARCH AND DEVELOPMENT AND SG&A EXPENSE GUIDANCE OF $1.50 TO $1.55 BILLION.QTRLY NON-GAAP NET INCOME PER SHARE - DILUTED $1.09.QTRLY GAAP EARNINGS PER SHARE $0.50.QTRLY TOTAL NET CF PRODUCT REVENUES $783 MILLION VERSUS $550 MILLION.QTRLY TOTAL REVENUES $784.5 MILLION VERSUS $578.2 MILLION.Q3 EARNINGS PER SHARE VIEW $1.02, REVENUE VIEW $790.9 MILLION -- THOMSON REUTERS I/B/E/S.QTRLY NON-GAAP EARNINGS PER SHARE $1.09.  Full Article

Vertex Receives European CHMP Positive Opinion For KALYDECO (Ivacaftor)
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Vertex Pharmaceuticals (Europe) Limited::VERTEX RECEIVES EUROPEAN CHMP POSITIVE OPINION FOR KALYDECO® (IVACAFTOR) TO TREAT PATIENTS WITH CYSTIC FIBROSIS AGED 12 TO <24 MONTHS WITH CERTAIN MUTATIONS IN THE CFTR GENE.VERTEX PHARMACEUTICALS (EUROPE) LIMITED - SUBMISSION FOR KALYDECO (IVACAFTOR) SUPPORTED BY DATA FROM CO'S ONGOING PHASE 3 OPEN-LABEL SAFETY STUDY.  Full Article

Vertex Completes Enrollment Of Two Phase 3 Studies Of Vx-659 In Triple Combination With Tezacaftor And Ivacaftor For The Treatment Of Cystic Fibrosis
Thursday, 6 Sep 2018 

Sept 6 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX COMPLETES ENROLLMENT OF TWO PHASE 3 STUDIES OF VX-659 IN TRIPLE COMBINATION WITH TEZACAFTOR AND IVACAFTOR FOR THE TREATMENT OF CYSTIC FIBROSIS.VERTEX PHARMACEUTICALS INC - DATA EXPECTED IN LATE 2018 FROM PHASE 3 STUDIES OF VX-659, TEZACAFTOR AND IVACAFTOR.VERTEX PHARMACEUTICALS INC - DATA FOR BOTH STUDIES OF VX-445, TEZACAFTOR AND IVACAFTOR EXPECTED IN Q1 OF 2019.VERTEX PHARMACEUTICALS - PLANS TO EVALUATE VX-659, VX-445 TRIPLE COMBINATION DATA TO CHOOSE BEST REGIMEN TO SUBMIT FOR POTENTIAL REGULATORY APPROVAL.VERTEX PHARMACEUTICALS - EXPECTS TO COMPLETE ENROLLMENT IN TWO PHASE 3 STUDIES OF VX-445 IN TRIPLE COMBINATION WITH TEZACAFTOR, IVACAFTOR IN Q4 2018.  Full Article

CRISPR And Vertex Provide Update On FDA Review Of Investigational NDA
Thursday, 31 May 2018 

May 30 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND VERTEX PROVIDE UPDATE ON FDA REVIEW OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTX001 FOR THE TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS-PLANNED INITIATION OF PHASE 1/2 TRIAL OF CTX001 IN EUROPE IN ADULT PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA IS UNCHANGED.CRISPR THERAPEUTICS AG - U.S FDA HAS PLACED A CLINICAL HOLD ON IND FOR CTX001 FOR TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS AG - COMPANIES EXPECT TO INITIATE PHASE 1/2 TRIAL OF CTX001 IN SECOND HALF OF 2018.  Full Article

Vertex posts positive data from cystic fibrosis triple combo trials

Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.